...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants
【24h】

Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants

机译：通过同时接种无毒的光滑bvrS / bvrR和粗糙的wbkA突变体来提高小鼠抗布鲁氏菌流产感染疫苗的功效

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The Brucella abortus S19 and RB51 strains are the most widely used live vaccines against bovine brucellosis. However, both can induce abortion and milk excretion, S19 vaccination interferes in serological tests, and RB51 is less effective. We have shown previously that a rough wbkAB. abortus mutant is attenuated and a better vaccine than RB51 in BALB/c mice, and that mutants in the two-component regulatory system bvrS/bvrR are markedly attenuated while keeping a smooth lipopolysaccharide (S-LPS). In this work, we tested whether simultaneous inoculation with live bvrS increases wbkA vaccine efficacy in mice. Even at high doses, the bvrS mutant was cleared much faster from spleens than the wbkA mutant. The splenic persistence of the wbkA mutant increased when inoculated along with the bvrS mutant, but also with inactivated bvrS cells or with purified B. abortus S-LPS, strongly suggesting that S-LPS in the bvrS mutant played a determinant role in the wbkA persistence. When inoculated alone, both mutants protected against virulent B. abortus but less than when inoculated simultaneously, and the protection afforded by the combination was better than that obtained with B. abortus S19. Increased protection was also obtained after simultaneous inoculation of the wbkA mutant and inactivated bvrS cells or purified S-LPS, showing again the role played by the S-LPS in the bvrS cells. In mice, the bvrS-wbkA combination induced an antibody response reduced with respect to B. abortus S19 vaccination. Thus, the simultaneous use of live bvrS and wbkA B. abortus mutants seems a promising approach to overcome the problems of the S19 andRB51 vaccines.
机译：流产布鲁氏菌S19和RB51菌株是针对牛布鲁氏菌病使用最广泛的活疫苗。但是，两者都可以引起流产和排乳，S19疫苗接种会干扰血清学检测，而RB51效果较差。前面我们已经显示了一个粗糙的wbkAB。与BALB / c小鼠中的RB51相比，流产突变体的减毒效果更好，且疫苗效果更好，并且在保持光滑脂多糖（S-LPS）的同时，两组分调节系统bvrS / bvrR中的突变体减毒效果明显。在这项工作中，我们测试了同时接种活bvrS是否会增加wbkA疫苗在小鼠中的功效。即使在高剂量下，bvrS突变体的脾脏清除速度也比wbkA突变体快得多。与bvrS突变体一起接种时，wbkA突变体的脾脏持久性增加，但与灭活的bvrS细胞或纯化的流产双歧杆菌S-LPS一起，脾脏持久性也增加，这强烈表明bvrS突变体中的S-LPS在wbkA持久性中起决定性作用。当单独接种时，两个突变体均能抵抗强力流产双歧杆菌，但比同时接种时少，并且该组合提供的保护作用优于流产双歧杆菌S19。同时接种wbkA突变体和灭活的bvrS细胞或纯化的S-LPS后，也获得了增强的保护，再次显示了S-LPS在bvrS细胞中所起的作用。在小鼠中，bvrS-wbkA组合诱导了针对流产双歧杆菌S19疫苗接种的抗体反应减少。因此，同时使用活bvrS和wbkA流产布鲁氏菌突变体似乎是克服S19和RB51疫苗问题的一种有前途的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号